<DOC>
	<DOCNO>NCT00422682</DOCNO>
	<brief_summary>The purpose study assess safety establish maximum tolerate dose ( MTD ) combination BSI-201 chemotherapeutic regimen adult subject histologically cytologically document advanced solid tumor . Based data generate BiPar/Sanofi , conclude iniparib posse characteristic typical PARP inhibitor class . The exact mechanism yet fully elucidate , however base experiment tumor cell perform laboratory , iniparib novel investigational anti-cancer agent induces gamma-H2AX ( marker DNA damage ) tumor cell line , induces cell cycle arrest G2/M phase tumor cell line , potentiates cell cycle effect DNA damage modality tumor cell line . Investigations potential target iniparib metabolite ongoing .</brief_summary>
	<brief_title>A Study Evaluating BSI-201 Combination With Chemotherapeutic Regimens Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Iniparib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>≥ 18 year old histologically cytologically document , advance solid tumor Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 Absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9/L ( without granulocyte colonystimulating factor [ GCSF ] support within 2 week study day 1 ) ; platelet count ≥ 100.0 x 10^9/L ( without transfusion within 2 week study day 1 ) ; hemoglobin ≥ 9.0 g/dL ( erythropoietic agent allow ) At least 14day period end last dose chemotherapy receive Any prior toxicity prior chemotherapeutic treatment recover ≤ grade 1 Subject enrol another investigational device drug trial , receive investigational agent Hematological malignancy Symptomatic untreated brain metastasis require concurrent treatment , inclusive limited surgery , radiation , corticosteroid . History seizure disorder Myocardial infarction ( MI ) within 6 month study day 1 , unstable angina , congestive heart failure ( CHF ) New York Heart Association ( NYHA ) &gt; class II , uncontrolled hypertension Concurrent prior ( within 7 day study day 1 ) anticoagulation therapy ( low dose port maintenance allow ) Specified concomitant medication Serum creatinine &gt; 1.5 x upper limit normal ( ULN ) Elevated liver enzyme ( AST/ALT ) &gt; 2.5 x ULN , &gt; 5.0 x ULN secondary liver metastasis ; alkaline phosphatase &gt; 2.5 x ULN &gt; 5.0 x ULN secondary liver bone metastases ; total bilirubin &gt; 1.5 x ULN Radiation therapy within 14 day study day 1 Antibody therapy treatment underlying malignancy within 14 day study day 1 Concurrent radiation therapy permit throughout course study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Solid tumor</keyword>
</DOC>